Cargando…
Vemurafenib as bridging therapy of hairy cell leukemia in a Jehovah’s Witness patient
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8720736/ https://www.ncbi.nlm.nih.gov/pubmed/33438048 http://dx.doi.org/10.1007/s00277-021-04403-4 |
_version_ | 1784625186533801984 |
---|---|
author | Schlaweck, Sebastian Brossart, Peter Heine, Annkristin |
author_facet | Schlaweck, Sebastian Brossart, Peter Heine, Annkristin |
author_sort | Schlaweck, Sebastian |
collection | PubMed |
description | |
format | Online Article Text |
id | pubmed-8720736 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-87207362022-01-13 Vemurafenib as bridging therapy of hairy cell leukemia in a Jehovah’s Witness patient Schlaweck, Sebastian Brossart, Peter Heine, Annkristin Ann Hematol Letter to the Editor Springer Berlin Heidelberg 2021-01-12 2022 /pmc/articles/PMC8720736/ /pubmed/33438048 http://dx.doi.org/10.1007/s00277-021-04403-4 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Letter to the Editor Schlaweck, Sebastian Brossart, Peter Heine, Annkristin Vemurafenib as bridging therapy of hairy cell leukemia in a Jehovah’s Witness patient |
title | Vemurafenib as bridging therapy of hairy cell leukemia in a Jehovah’s Witness patient |
title_full | Vemurafenib as bridging therapy of hairy cell leukemia in a Jehovah’s Witness patient |
title_fullStr | Vemurafenib as bridging therapy of hairy cell leukemia in a Jehovah’s Witness patient |
title_full_unstemmed | Vemurafenib as bridging therapy of hairy cell leukemia in a Jehovah’s Witness patient |
title_short | Vemurafenib as bridging therapy of hairy cell leukemia in a Jehovah’s Witness patient |
title_sort | vemurafenib as bridging therapy of hairy cell leukemia in a jehovah’s witness patient |
topic | Letter to the Editor |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8720736/ https://www.ncbi.nlm.nih.gov/pubmed/33438048 http://dx.doi.org/10.1007/s00277-021-04403-4 |
work_keys_str_mv | AT schlawecksebastian vemurafenibasbridgingtherapyofhairycellleukemiainajehovahswitnesspatient AT brossartpeter vemurafenibasbridgingtherapyofhairycellleukemiainajehovahswitnesspatient AT heineannkristin vemurafenibasbridgingtherapyofhairycellleukemiainajehovahswitnesspatient |